CA2620960A1 - 3, nb dihydrotetrabanezine for the treatment of schizophrenia and other psychoses - Google Patents

3, nb dihydrotetrabanezine for the treatment of schizophrenia and other psychoses Download PDF

Info

Publication number
CA2620960A1
CA2620960A1 CA002620960A CA2620960A CA2620960A1 CA 2620960 A1 CA2620960 A1 CA 2620960A1 CA 002620960 A CA002620960 A CA 002620960A CA 2620960 A CA2620960 A CA 2620960A CA 2620960 A1 CA2620960 A1 CA 2620960A1
Authority
CA
Canada
Prior art keywords
dihydrotetrabenazine
cndot
cis
compound
psychosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002620960A
Other languages
English (en)
French (fr)
Inventor
Andrew John Duffield
Jean Elizabeth Yarrow
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valeant Laboratories International Bermuda SRL
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0516167.4A external-priority patent/GB0516167D0/en
Priority claimed from GB0516790A external-priority patent/GB0516790D0/en
Application filed by Individual filed Critical Individual
Publication of CA2620960A1 publication Critical patent/CA2620960A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002620960A 2005-08-06 2006-08-04 3, nb dihydrotetrabanezine for the treatment of schizophrenia and other psychoses Abandoned CA2620960A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0516167.4 2005-08-06
GBGB0516167.4A GB0516167D0 (en) 2005-08-06 2005-08-06 Pharmaceutical compounds
GB0516790.3 2005-08-16
GB0516790A GB0516790D0 (en) 2005-08-16 2005-08-16 Pharmaceutical compounds
PCT/GB2006/002936 WO2007017654A1 (en) 2005-08-06 2006-08-04 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Publications (1)

Publication Number Publication Date
CA2620960A1 true CA2620960A1 (en) 2007-02-15

Family

ID=37400949

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002620960A Abandoned CA2620960A1 (en) 2005-08-06 2006-08-04 3, nb dihydrotetrabanezine for the treatment of schizophrenia and other psychoses

Country Status (20)

Country Link
US (1) US20110257220A1 (cg-RX-API-DMAC7.html)
EP (2) EP2050451B1 (cg-RX-API-DMAC7.html)
JP (1) JP2009504622A (cg-RX-API-DMAC7.html)
KR (1) KR20080033500A (cg-RX-API-DMAC7.html)
AT (2) ATE534391T1 (cg-RX-API-DMAC7.html)
AU (1) AU2006277753B2 (cg-RX-API-DMAC7.html)
CA (1) CA2620960A1 (cg-RX-API-DMAC7.html)
CY (1) CY1108843T1 (cg-RX-API-DMAC7.html)
DE (1) DE602006004009D1 (cg-RX-API-DMAC7.html)
DK (1) DK1855677T3 (cg-RX-API-DMAC7.html)
ES (1) ES2318771T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20090074T3 (cg-RX-API-DMAC7.html)
MX (1) MX2008001549A (cg-RX-API-DMAC7.html)
NZ (1) NZ566011A (cg-RX-API-DMAC7.html)
PL (1) PL1855677T3 (cg-RX-API-DMAC7.html)
PT (1) PT1855677E (cg-RX-API-DMAC7.html)
RS (1) RS50807B (cg-RX-API-DMAC7.html)
RU (1) RU2407743C2 (cg-RX-API-DMAC7.html)
SI (1) SI1855677T1 (cg-RX-API-DMAC7.html)
WO (1) WO2007017654A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2081929E (pt) 2006-11-08 2013-04-15 Neurocrine Biosciences Inc Compostos de 3-isobutil-9,10-dimetoxi- 1,3,4,6,7,11b-hexahidro-2h-pirido[2,1-a]isoquinolin- 2-ol substituídos e métodos com estes relacionados
US8008500B2 (en) 2007-06-08 2011-08-30 General Electric Company Intermediates useful for making tetrabenazine compounds
US8053578B2 (en) 2007-11-29 2011-11-08 General Electric Company Alpha-fluoroalkyl dihydrotetrabenazine imaging agents and probes
GB0810857D0 (en) * 2008-06-13 2008-07-23 Cambridge Lab Ireland Ltd Pharmaceutical compounds
GB2463451A (en) * 2008-09-08 2010-03-17 Cambridge Lab 3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
GB2463283A (en) * 2008-09-08 2010-03-10 Cambridge Lab 3,11b-cis-dihydrotetrabenazine for use in treating asthma
CA2801061A1 (en) 2010-06-01 2011-12-08 Auspex Pharmaceuticals, Inc. Benzoquinolone inhibitors of vmat2
KR101882044B1 (ko) 2011-04-01 2018-07-25 쓰리엠 이노베이티브 프로퍼티즈 캄파니 트라이아진계 자외선 흡수제를 포함하는 필름
EP3099299A4 (en) 2014-01-27 2017-10-04 Auspex Pharmaceuticals, Inc. Benzoquinoline inhibitors of vesicular monoamine transporter 2
RU2021128797A (ru) * 2014-02-07 2021-11-26 Ньюрокрайн Байосайенсиз, Инк. Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
JP7109360B2 (ja) 2015-10-30 2022-07-29 ニューロクライン バイオサイエンシーズ，インコーポレイテッド バルベナジン塩およびその多形体
CA3009169A1 (en) 2015-12-23 2017-06-29 Neurocrine Biosciences, Inc. Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
JP2020500875A (ja) * 2016-12-02 2020-01-16 ニューロクライン バイオサイエンシーズ，インコーポレイテッド 統合失調症または統合失調感情障害を処置するためのバルベナジンの使用
EA201991782A1 (ru) 2017-01-27 2021-09-23 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
GB201705306D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705304D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705302D0 (en) * 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
GB201705303D0 (en) 2017-04-01 2017-05-17 Adeptio Pharmaceuticals Ltd Pharmaceutical compositions
CN111372567B (zh) 2017-09-21 2024-03-15 纽罗克里生物科学有限公司 高剂量的缬苯那嗪制剂和与其相关的组合物、方法和试剂盒
WO2019074492A1 (en) 2017-10-10 2019-04-18 Obrien Christopher F METHODS OF ADMINISTRATION OF CERTAIN VMAT2 INHIBITORS
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
GB201808464D0 (en) 2018-05-23 2018-07-11 Adeptio Pharmaceuticals Ltd Pharmaceutical compounds for use in treating huntington's disease
IL320987A (en) 2018-08-15 2025-07-01 Neurocrine Biosciences Inc Methods for the administration of certain vmat2 inhibitors
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2830993A (en) 1958-04-15 Quinolizine derivatives
US2843591A (en) * 1958-07-15 Method for preparing same
CA2058640A1 (en) * 1991-01-25 1992-07-26 Richard R. Scherschlicht Tricyclic pyridone derivative
US6087376A (en) * 1997-02-05 2000-07-11 University Of Kentucky Research Foundation Use of lobeline compounds in the treatment of central nervous system diseases and pathologies
FR2770215B1 (fr) * 1997-10-28 2000-01-14 Pf Medicament Derives d'aminomethyl-benzo[a]quinolizidine, leur preparation et leur application en therapeutique pour les maladies neurodegeneratives
GB2410947B (en) * 2004-02-11 2008-09-17 Cambridge Lab Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
ATE415968T1 (de) 2008-12-15
RS50807B (sr) 2010-08-31
NZ566011A (en) 2011-01-28
AU2006277753A1 (en) 2007-02-15
CY1108843T1 (el) 2014-07-02
DE602006004009D1 (de) 2009-01-15
HK1111083A1 (en) 2008-08-01
EP2050451B1 (en) 2011-11-23
HRP20090074T3 (en) 2009-04-30
JP2009504622A (ja) 2009-02-05
EP1855677B1 (en) 2008-12-03
RU2407743C2 (ru) 2010-12-27
SI1855677T1 (sl) 2009-04-30
KR20080033500A (ko) 2008-04-16
WO2007017654A1 (en) 2007-02-15
MX2008001549A (es) 2008-04-04
EP2050451A1 (en) 2009-04-22
EP1855677A1 (en) 2007-11-21
RU2008108623A (ru) 2009-09-20
US20110257220A1 (en) 2011-10-20
ATE534391T1 (de) 2011-12-15
ES2318771T3 (es) 2009-05-01
AU2006277753B2 (en) 2011-11-10
PL1855677T3 (pl) 2009-07-31
DK1855677T3 (da) 2009-02-09
PT1855677E (pt) 2009-01-13

Similar Documents

Publication Publication Date Title
AU2006277753B2 (en) 3, hb cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
US7956065B2 (en) Pharmaceutical compounds
US20080108645A1 (en) Dihydrotetrabenazines And Pharmaceutical Compositions Containing Them
GB2463452A (en) Desmethyl derivatives of tetrabenazine and pharmaceutical compositions thereof
EP1885363B1 (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
US20110039877A1 (en) Use of 3, 11b-cis-dihydrotetrabenazine in the treatment of multiple sclerosis and autoimmune myelitis
WO2009150474A1 (en) Dihydrotetrabenanzine for the treatment of anxiety
HK1125575A (en) 3,11b cis dihydrotetrabanezine for the treatment of psychoses
HK1111083B (en) 3,11b cis dihydrotetrabanezine for the treatment of schizophrenia and other psychoses
CN101351205A (zh) 治疗精神分裂症及其它精神病的3,11b-顺式-二氢丁苯那嗪
HK1111085B (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington' s disease
HK1121972A (en) Use of 3,11b-cis-dihydrotetrabenazine for the treatment of symptoms of huntington's disease

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20130806